LYON, France, Jan. 20, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today placement of the first Sonolith i-sys electroconductive lithotripter in South Africa.
Pretoria Urology Hospital (PUH) is the largest private urology hospital in South Africa, entirely dedicated to treating urology disorders ranging from urinary stones to prostate cancer. A medical team of fourteen urologists at PUH is actively focusing on offering best-in-class treatment options to patients and has been using EDAP's Ablatherm-HIFU technology to successfully treat prostate cancer for over a year. More than 600 lithotripsy treatments are performed every year at PUH, together with associated endourology procedures. Sonolith i-sys fully integrated system is the ideal treatment to meet PUH's lithotripsy needs.
Mr. Gary Wachsberger, Director of Intamed, EDAP's distribution partner in South Africa, commented, "We have enjoyed a long term relationship with EDAP to distribute their best-in-class urology devices in South Africa and have successfully introduced the Company's Ablatherm-HIFU device. We are excited to now place the first electroconductive Sonolith i-sys in South Africa. Its compelling efficacy and superiority will allow patients to benefit from the industry leading technology to treat their urinary stones. We are very optimistic about additional placement opportunities for EDAP's range of Sonolith devices."Marc Oczachowski, Chief Executive Officer of EDAP, added, "We are actively pursuing our global expansion strategy of entering new and growing markets. We are very excited to move forward the entry of EDAP in the major African markets, with the first installation of our innovative and leading integrated lithotripsy system, the Sonolith i-sys. This is another successful milestone in our aggressive strategy to penetrate new markets and take more market share thanks to our unique and fully renewed range of lithotripters." Marc Oczachowski concluded, "We continue to work actively on pushing forward our regulatory programs in major markets and are on track for Sonolith i-move approvals in the U.S. and major international markets."